CN118451082A - N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-N'-甲氧基脲的乙醇溶剂化物的结晶形式 - Google Patents

N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-N'-甲氧基脲的乙醇溶剂化物的结晶形式 Download PDF

Info

Publication number
CN118451082A
CN118451082A CN202280069988.XA CN202280069988A CN118451082A CN 118451082 A CN118451082 A CN 118451082A CN 202280069988 A CN202280069988 A CN 202280069988A CN 118451082 A CN118451082 A CN 118451082A
Authority
CN
China
Prior art keywords
compound
crystalline form
disorder
xiv
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280069988.XA
Other languages
English (en)
Chinese (zh)
Inventor
P·I·弗拉霍瓦
J·尼尔森
M·T·布兰德
A·森特什
Z·卡苏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Pharma Switzerland GmbH
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Switzerland GmbH, Richter Gedeon Nyrt filed Critical Sumitomo Pharma Switzerland GmbH
Publication of CN118451082A publication Critical patent/CN118451082A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280069988.XA 2021-10-18 2022-10-18 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-N'-甲氧基脲的乙醇溶剂化物的结晶形式 Pending CN118451082A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163257073P 2021-10-18 2021-10-18
US63/257,073 2021-10-18
PCT/EP2022/078989 WO2023066941A1 (en) 2021-10-18 2022-10-18 Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea

Publications (1)

Publication Number Publication Date
CN118451082A true CN118451082A (zh) 2024-08-06

Family

ID=84359608

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280069988.XA Pending CN118451082A (zh) 2021-10-18 2022-10-18 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-N'-甲氧基脲的乙醇溶剂化物的结晶形式

Country Status (5)

Country Link
US (1) US20250066382A1 (https=)
EP (1) EP4419530A1 (https=)
JP (1) JP2024540922A (https=)
CN (1) CN118451082A (https=)
WO (1) WO2023066941A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3518933B2 (en) 2016-09-30 2025-02-26 Sumitomo Pharma Switzerland GmbH Methods of treating uterine fibroids and endometriosis
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1591446B1 (en) 2003-01-29 2013-03-06 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
PL2900675T3 (pl) 2012-09-28 2019-08-30 Takeda Pharmaceutical Company Limited Sposób wytwarzania pochodnej tienopirymidyny
CA2978223A1 (en) 2015-02-26 2016-09-01 Takeda Pharmaceutical Company Limited Formulations of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethyl amino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
EP3518933B2 (en) 2016-09-30 2025-02-26 Sumitomo Pharma Switzerland GmbH Methods of treating uterine fibroids and endometriosis
CN110248661A (zh) 2016-09-30 2019-09-17 梦欧文科学有限责任公司 前列腺癌的治疗
WO2019178304A1 (en) * 2018-03-14 2019-09-19 Teva Pharmaceuticals International Gmbh Solid state forms of relugolix
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
EP4041738A1 (en) 2019-10-10 2022-08-17 Myovant Sciences GmbH Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea

Also Published As

Publication number Publication date
WO2023066941A1 (en) 2023-04-27
US20250066382A1 (en) 2025-02-27
JP2024540922A (ja) 2024-11-06
EP4419530A1 (en) 2024-08-28

Similar Documents

Publication Publication Date Title
CN118451082A (zh) N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-N'-甲氧基脲的乙醇溶剂化物的结晶形式
RU2507202C2 (ru) Новые фенилпиразиноны в качестве ингибиторов киназы
WO2022177917A2 (en) Compositions and methods for inhibition of ras
US20240174690A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
EP4043463B1 (en) Fused ring derivative having mgat-2 inhibitory activity
CA2687608C (en) Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
US20220372044A1 (en) Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
WO2021113661A1 (en) Amorphous and polymorphic form of a specific chk1 inhibitor
HUP0103546A2 (hu) sPLA2 inhibitor hatású pirrolo[1,2-b] piridazinok és ezeket tartalmazó gyógyszerkészítmények
JP2005507911A (ja) 自己免疫疾患の処置のためのシクロスポリンアナログ
AU2006327871A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
EP2581373A1 (en) Benzo- or pyrido-imidazole derivative
EP4041739A1 (en) Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'- methoxyurea
JPH11511482A (ja) 免疫抑制活性を有するトリテルペン誘導体
CN115551836A (zh) 嘧啶环己基糖皮质激素受体调节剂的多晶型物
JPH08506356A (ja) 抗癌遺伝子剤および抗癌剤としてのアンサマイシン誘導体
CN116003505B (zh) 双氢青蒿素-熊去氧胆酸缀合物的多晶型物及其制备方法和应用
RS20060196A (sr) Imidazopiridinski derivati kao inhibitori inducibilne no-sintaze
CN117751099A (zh) 酰胺类化合物及其应用
CN117157290A (zh) 用于抑制kras的组合物及方法
EP4585588A1 (en) Benzimidazole compound, and preparation method therefor and use thereof
US3772283A (en) 3,5-androstadieno-(3,4-d)-2'-imino-3'-substituted)-thiazolines,isomers thereof,methods for their manufacture and intermediates useful therein
KR20250127754A (ko) 에버멕틴 유도체
HK40104894A (zh) 用於抑制kras的组合物及方法
HK40126927A (en) Avermectin derivative

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: P.I. Flahova

Inventor after: J NILSSON

Inventor after: M. T. Brand

Inventor after: A. Sentesh

Inventor after: Z. Kasu

Inventor after: A. Demit

Inventor before: P.I. Flahova

Inventor before: J NILSSON

Inventor before: M. T. Brand

Inventor before: A. Sentesh

Inventor before: Z. Kasu

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20260304

Address after: Osaka

Applicant after: SUMITOMO PHARMACEUTICALS CO.,LTD.

Country or region after: Japan

Applicant after: RICHTER GEDEON NYRT.

Country or region after: Hungary

Address before: Basel

Applicant before: Sumitomo Pharmaceutical Switzerland Ltd.

Country or region before: Switzerland

Applicant before: RICHTER GEDEON NYRT.

Country or region before: Hungary